Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Carasent

27.05 SEK

-0.73 %

1,644 following

CARA

NASDAQ Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
-0.73 %
-1.28 %
-0.73 %
-5.75 %
+21.85 %
+30.66 %
+58.27 %
-1.89 %
+22.30 %

Carasent is an IT company. The company delivers a wide range of products and services in communication and IT infrastructure specifically aimed at the healthcare industry. Examples of solutions include proprietary cloud-based services, email management, mobile solutions, and security solutions. Customers are mainly found in health and care, finance, and telecom. The company was originally established in 1997 and is headquartered in Gothenburg.

Read more
Market cap
1.96B SEK
Turnover
573.46K SEK
Revenue
267.75M
EBIT %
-19.8 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
12/2
2026

Annual report '25

14/4
2026

Interim report Q1'26

20/4
2026

General meeting '26

All
Webcasts
Press releases
ShowingAll content types
Regulatory press release10/22/2025, 10:50 AM

Carasent AB (publ) Nomination Committee for the Annual General Meeting 2026

Carasent
Regulatory press release10/22/2025, 10:50 AM

Carasent AB (publ) Valberedning inför årsstämman 2026

Carasent
Press release10/17/2025, 5:42 AM

DNB Carnegie Access: Carasent: Margins starting to unfold – Q3 review

Carasent

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release10/16/2025, 6:24 PM

Redeye: Carasent (Q3 Review) - In good shape for exciting 2026

Carasent
Press release10/16/2025, 6:54 AM

DNB Carnegie Access: Carasent: The margin we wanted to see – Q3 initial

Carasent
Carasent, Audiocast, Q3'25
Webcast10/16/2025, 6:00 AM

Carasent, Audiocast, Q3'25

Carasent
Regulatory press release10/16/2025, 5:00 AM

Carasent AB (publ) – Interim report January–September 2025

Carasent
Regulatory press release10/16/2025, 5:00 AM

Carasent AB (publ) – Delårsrapport Januari–September 2025

Carasent
Regulatory press release10/10/2025, 8:00 AM

Carasent AB (publ) – Invitation to presentation of Q3 2025 results

Carasent
Regulatory press release10/10/2025, 8:00 AM

Carasent AB (publ) – Inbjudan till presentation av det tredje kvartalet 2025

Carasent
Regulatory press release10/8/2025, 7:41 AM

Finansinspektionen: Flaggningsmeddelande i Carasent AB (publ)

Carasent
Press release10/1/2025, 5:34 AM

DNB Carnegie Access: Carasent: Eyeing margins in H2 – Q3 preview

Carasent
Press release9/4/2025, 6:19 AM

DNB Carnegie Access: Carasent: Highlights from DNB Carnegie’s Small & Mid Cap seminar

Carasent
Press release7/11/2025, 9:55 AM

Redeye: Carasent - Solid ARR despite lowered target

Carasent
Press release7/11/2025, 5:13 AM

DNB Carnegie Access: Carasent: Every cloud has a silver lining – Q2 review

Carasent
Press release7/10/2025, 6:01 AM

DNB Carnegie Access: Carasent: Full figures in line with pre-announcement – Q2 initial

Carasent
Carasent, Audiocast, Q2'25
Webcast7/10/2025, 6:00 AM

Carasent, Audiocast, Q2'25

Carasent
Regulatory press release7/10/2025, 5:00 AM

Carasent AB (publ) – Halvårsrapport Januari–Juni 2025

Carasent
Regulatory press release7/10/2025, 5:00 AM

Carasent AB (publ) – Interim report January–June 2025

Carasent
Regulatory press release7/9/2025, 5:00 PM

Carasent initiates SEK 150 million share buy-back program

Carasent
Forum discussions
Carnegielta commissioned research pre-Q4 Inderes Carnegie Access: Carasent: We expect a solid end to the year – Q4 preview -... Carnegie has published a new commissioned research report on Carasent.To access the full report and subscribe to future updates, visit https://www.carnegie...
1/29/2025, 6:41 AM
by timontti
6
redeye.se Carasent (Q3 Review): In good shape for exciting 2026 Redeye retains its positive view of Carasent following the Q3 report. Organic ARR growth remains solid, and margins are improving substantially. The company has several ongoing growth initiatives tha Carasent’s profitability...
10/16/2025, 3:46 PM
by Diviner
2
I have thousands of euros worth of Carasent ASA. It is no longer traded, so I am stuck with the shares. I thought there would have been an automatic exchange to Carasent AB… Is anyone else in the same situation? What should I do? How can I prevent this in the future?
6/23/2025, 7:38 AM
by Loue
1
redeye.se Carasent: Back in Shape in 2024 – More to Come Redeye retains its positive view of Carasent following the Q4 report. Despite a somewhat softer Q4 report than expected and a softened outlook for H1 2025, we changed our Base Case driven by revised New Base Case SEK28 (NOK26...
2/17/2025, 6:47 AM
by timontti
1
Redeye odotuksia 13.2. osariin
2/6/2025, 3:08 PM
by timontti
1
Inderes First day of trading in Carasent AB (publ) on Nasdaq Stockholm - Inderes NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND...
12/9/2024, 9:27 AM
by timontti
1
Which intermediary? Contact them, and the matter should be resolved.
6/23/2025, 1:51 PM
by Turskanpyytäjä
0
Read more on our forum
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.